Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Catabasis Pharmaceuticals, Gates MRI enter agreement to assess CAT-5571 for TB » 08:14
08/04/20
08/04
08:14
08/04/20
08:14
CATB

Catabasis Pharmaceuticals

$6.07 /

+0.29 (+5.02%)

Catabasis Pharmaceuticals…

Catabasis Pharmaceuticals announced it entered into an agreement with the Bill & Melinda Gates Medical Research Institute, or Gates MRI, a non-profit biotechnology organization, to assess CAT-5571 as a potential oral therapy to promote autophagy and clear persistent lung infections in patients with both drug-sensitive and drug-resistant tuberculosis, or TB. Catabasis granted Gates MRI a non-exclusive license to CAT-5571, and will furnish samples of CAT-5571 to conduct this preclinical collaboration research program. Mycobacterium tuberculosis, or Mtb, is known to cause TB. CAT-5571 will be studied alone and in combination with the standard of care regimen in cell and animal models of Mtb infection to determine the potential for CAT-5571 to induce autophagy and encourage Mtb elimination as well as to assess its contribution to TB drug regimens and durations. In previous preclinical studies, CAT-5571 was shown to restore autophagy in mouse and human cells with the delta508-CFTR mutation and promote the clearance of bacteria, including Mycobacterium abscessus, from these cells. Evidence suggests that autophagy plays a role in antimycobacterial resistance in TB by acting as an alternative mechanism to control Mtb infection in macrophages, as well as to defend and counteract Mtb evasion strategies. "We are thrilled to work with Gates MRI to expand our understanding of CAT-5571," said Andrew

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$6.07 /

+0.29 (+5.02%)

CATB Catabasis Pharmaceuticals
$6.07 /

+0.29 (+5.02%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
CATB Catabasis Pharmaceuticals
$6.07 /

+0.29 (+5.02%)

  • 30
    Jan
Over a month ago
Hot Stocks
Catabasis Pharmaceuticals joins Russell 3000 Index » 16:10
06/29/20
06/29
16:10
06/29/20
16:10
CATB

Catabasis Pharmaceuticals

$6.92 /

-0.135 (-1.91%)

Catabasis Pharmaceuticals…

Catabasis Pharmaceuticals announced that it has joined the broad-market Russell 3000 Index at the conclusion of the 2020 Russell Indexes annual reconstitution, effective after the US market opened today.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$6.92 /

-0.135 (-1.91%)

CATB Catabasis Pharmaceuticals
$6.92 /

-0.135 (-1.91%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
CATB Catabasis Pharmaceuticals
$6.92 /

-0.135 (-1.91%)

  • 30
    Jan
Hot Stocks
Catabasis Pharmaceuticals names Ben Harshbarger as General Counsel » 08:03
06/12/20
06/12
08:03
06/12/20
08:03
CATB

Catabasis Pharmaceuticals

$6.19 /

-0.67 (-9.77%)

Catabasis Pharmaceuticals…

Catabasis Pharmaceuticals announced that it has named Ben Harshbarger as Senior Vice President, General Counsel. Mr. Harshbarger most recently served as the Interim Chief Executive Officer and General Counsel at Novelion Therapeutics.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$6.19 /

-0.67 (-9.77%)

CATB Catabasis Pharmaceuticals
$6.19 /

-0.67 (-9.77%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
CATB Catabasis Pharmaceuticals
$6.19 /

-0.67 (-9.77%)

Over a quarter ago
Hot Stocks
Catabasis Pharmaceuticals shares edasalonexent program information at MDA » 08:13
05/12/20
05/12
08:13
05/12/20
08:13
CATB

Catabasis Pharmaceuticals

$6.00 /

-0.12 (-1.96%)

Catabasis Pharmaceuticals…

Catabasis Pharmaceuticals shared information on the edasalonexent program in Phase 3 development for the treatment of Duchenne muscular dystrophy, or DMD, in poster presentations at the 2020 Muscular Dystrophy Association, or MDA, Virtual Poster Session. The three posters include an analysis of the baseline characteristics of patients enrolled in the Phase 3 PolarisDMD trial, age-normative growth and normal adrenal function seen in the Phase 2 MoveDMD trial and open-label extension, and experience with capsule swallowing in both clinical trials for edasalonexent in boys with DMD. Top-line results from the Phase 3 trial are expected in Q4. An analysis of the baseline characteristics of the patients enrolled in the Phase 3 PolarisDMD trial was performed compared to the patients enrolled in the previous Phase 2 MoveDMD trial and found overall similar baseline characteristics in the patient populations in the two trials. Both the Phase 3 PolarisDMD trial and the Phase 2 MoveDMD trial enrolled boys affected by DMD ages four to seven with any mutation type who had not been on steroids for the previous six months. There were no significant differences between the two trials in baseline age, North Star Ambulatory Assessment, or NSAA, score and timed function test values. These findings are believed to support the assumptions on which the Phase 3 trial was powered. Catabasis also shared long-term safety and tolerability data from the MoveDMD trial and open-label extension. Edasalonexent was associated with age-normative growth, without negative impact on bone health, and normal adrenal function in boys with DMD as it does not impact the glucocorticoid receptor. There was no evidence of adrenal insufficiency for up to 150 weeks of edasalonexent treatment, and no clinically significant changes in cortisol or ACTH. Additionally, edasalonexent treatment in a mdx mouse model of DMD preserved bone length and bone density. In more than 100 years of cumulative patient exposure, edasalonexent has been well-tolerated, with no serious adverse events on treatment, and without the adverse effects associated with high-dose steroids. In both the Phase 2 MoveDMD trial and the ongoing Phase 3 PolarisDMD trial, 97% of four to seven year-old boys with DMD screened for the studies were able to swallow soft-gel study drug capsules. There have been no discontinuations due to capsule burden. This demonstrates that edasalonexent has the potential to be broadly adopted by those affected by DMD and supports the long-term safety and tolerability of edasalonexent.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$6.00 /

-0.12 (-1.96%)

CATB Catabasis Pharmaceuticals
$6.00 /

-0.12 (-1.96%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
CATB Catabasis Pharmaceuticals
$6.00 /

-0.12 (-1.96%)

Earnings
Catabasis Pharmaceuticals reports Q4 EPS (55c), two estimates (61c) » 08:19
03/10/20
03/10
08:19
03/10/20
08:19
CATB

Catabasis Pharmaceuticals

$4.70 /

-0.17 (-3.49%)

As of December 31, 2019,…

As of December 31, 2019, Catabasis had cash, cash equivalents and short-term investments of $36.2M, compared to $40.6M as of September 30, 2019. Following December 31, 2019, Catabasis raised an additional $27.6M from equity financings for $25.6M in net proceeds. Based on the company's current operating plan, Catabasis expects that it has sufficient cash to fund operations through a potential NDA filing and into Q3 2021.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$4.70 /

-0.17 (-3.49%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
Syndicate
Catabasis Pharmaceuticals 4.6M share Secondary priced at $5.00 » 09:19
01/30/20
01/30
09:19
01/30/20
09:19
CATB

Catabasis Pharmaceuticals

$5.73 /

+0.01 (+0.17%)

The transaction size was…

The transaction size was increased from $20M to $23M. Oppenheimer is acting as sole book running manager for the offering.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$5.73 /

+0.01 (+0.17%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
01/31/19 Wedbush
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
Syndicate
Catabasis Pharmaceuticals files to sell common stock, no amount given » 16:02
01/29/20
01/29
16:02
01/29/20
16:02
CATB

Catabasis Pharmaceuticals

$5.65 /

-0.07 (-1.22%)

Oppenheimer & Co.…

Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$5.65 /

-0.07 (-1.22%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
01/31/19 Wedbush
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
Syndicate
Catabasis Pharmaceuticals files to sell common stock, no amount given » 16:02
01/29/20
01/29
16:02
01/29/20
16:02
CATB

Catabasis Pharmaceuticals

$5.65 /

-0.07 (-1.22%)

Oppenheimer & Co.…

Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$5.65 /

-0.07 (-1.22%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
01/31/19 Wedbush
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
Syndicate
Catabasis Pharmaceuticals files to sell common stock, no amount given » 16:01
01/29/20
01/29
16:01
01/29/20
16:01
CATB

Catabasis Pharmaceuticals

$5.65 /

-0.07 (-1.22%)

Oppenheimer & Co.…

Oppenheimer & Co. Inc. is acting as sole underwriter for the offering.

ShowHide Related Items >><<
CATB Catabasis Pharmaceuticals
$5.65 /

-0.07 (-1.22%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
01/31/19 Wedbush
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
Conference/Events
Solebury Trout to hold an event » 04:55
01/16/20
01/16
04:55
01/16/20
04:55
ACRX

AcelRx

$2.00 /

+0.03 (+1.53%)

, XLRN

Acceleron

$54.29 /

-1.14 (-2.06%)

, AMRN

Amarin

$19.38 /

+0.06 (+0.31%)

, ASMB

Assembly Biosciences

$17.91 /

-0.61 (-3.29%)

, BHVN

Biohaven Pharmaceutical

$51.52 /

-0.475 (-0.91%)

, CASI

Casi Pharmaceuticals

$3.27 /

-0.02 (-0.61%)

, CATB

Catabasis Pharmaceuticals

$6.80 /

+0.16 (+2.41%)

, CPRX

Catalyst Pharmaceuticals

$4.39 /

+ (+0.00%)

, CBMG

Cellular Biomedicine

$17.46 /

-0.03 (-0.17%)

, ENZ

Enzo Biochem

$2.58 /

+0.045 (+1.78%)

, EPGNY

Epigenomics

$0.00 /

+ (+0.00%)

, EPIX

Essa Pharma

$5.69 /

-0.06 (-1.04%)

, EVFM

Evofem

$6.11 /

+0.05 (+0.83%)

, GNFTF

Genfit

$0.00 /

+ (+0.00%)

, GERN

Geron

$1.49 /

+0.055 (+3.83%)

, HCM

Hutchison China MediTech

$28.32 /

-0.01 (-0.04%)

, LCTX

Lineage Cell Therapeutics

$0.74 /

-0.0074 (-0.99%)

, MRKR

Marker Therapeutics

$3.06 /

-0.15 (-4.67%)

, MEIP

MEI Pharma

$2.36 /

+0.16 (+7.27%)

, WVE

Wave Life Sciences

$7.97 /

+0.11 (+1.40%)

, VTVT

vTv Therapeutics

$2.27 /

+0.24 (+11.82%)

, STRO

Sutro Biopharma

$11.83 /

+0.04 (+0.34%)

, SBBP

Strongbridge Biopharma

$2.30 /

+0.02 (+0.88%)

, SELB

Selecta Biosciences

$2.94 /

+ (+0.00%)

, RIGL

Rigel Pharmaceuticals

$2.73 /

+0.115 (+4.40%)

, PLSE

Pulse Biosciences

$14.24 /

+0.2 (+1.42%)

, PTGX

Protagonist Therapeutics

$7.16 /

+0.3 (+4.37%)

19th Annual 1:1…

19th Annual 1:1 Management Access Event will be held in San Francisco on January 13-16.

ShowHide Related Items >><<
ACRX AcelRx
$2.00 /

+0.03 (+1.53%)

11/11/19 Credit Suisse
Credit Suisse downgrades AcelRx to Neutral, cuts target to $2 from $7
11/11/19 Credit Suisse
AcelRx downgraded to Neutral from Outperform at Credit Suisse
08/05/19 Credit Suisse
AcelRx assumed with an Outperform at Credit Suisse
07/10/19 Credit Suisse
AcelRx assumed with an Outperform at Credit Suisse
XLRN Acceleron
$54.29 /

-1.14 (-2.06%)

01/08/20 Piper Sandler
Acceleron risk/reward into data heavily skewed to upside, says Piper Sandler
12/11/19 Piper Sandler
Piper Jaffray sees strong launch for Acceleron's Reblozyl
11/11/19 H.C. Wainwright
Acceleron price target raised to $88 from $68 at H.C. Wainwright
11/08/19 Piper Sandler
Acceleron approval signifies FDA confidence, says Piper Jaffray
AMRN Amarin
$19.38 /

+0.06 (+0.31%)

01/13/20 Roth Capital
Amarin's Vascepa now the 'go-to' after competitor failures, says Roth Capital
01/13/20 Stifel
Amarin should rally on failure of two potential competitors, says Stifel
01/13/20 JPMorgan
Epanova discontinuation positive for Amarin, says JPMorgan
01/10/20 Roth Capital
Amarin set up for strong partnership interest in the EU, says Roth Capital
ASMB Assembly Biosciences
$17.91 /

-0.61 (-3.29%)

10/17/19 Baird
Assembly Biosciences abstract data encouraging, says Baird
10/16/19
Fly Intel: Top five analyst initiations
10/16/19 Mizuho
Mizuho starts Assembly Biosciences with Buy rating, $20 target
10/15/19 Mizuho
Assembly Biosciences initiated with a Buy at Mizuho
BHVN Biohaven Pharmaceutical
$51.52 /

-0.475 (-0.91%)

12/23/19 Piper Sandler
Ubrelvy's label 'clearly bodes very well' for Biohaven's rimegepant, says Piper
12/17/19 Piper Sandler
Biohaven now has second, complementary CGRP product, says Piper Jaffray
12/06/19 SVB Leerink
Biohaven price target raised to $64 from $62 at SVB Leerink
12/06/19 Piper Sandler
Biohaven models should start adding value for Alzheimer's, says Piper Jaffray
CASI Casi Pharmaceuticals
$3.27 /

-0.02 (-0.61%)

CATB Catabasis Pharmaceuticals
$6.80 /

+0.16 (+2.41%)

11/08/19 Oppenheimer
Catabasis Pharmaceuticals price target lowered to $60 from $72 at Oppenheimer
01/31/19 Wedbush
Catabasis Pharmaceuticals price target raised to $28 from $3 at Wedbush
CPRX Catalyst Pharmaceuticals
$4.39 /

+ (+0.00%)

11/13/19 Piper Sandler
Catalyst Pharmaceuticals price target lowered to $7 from $8 at Piper Jaffray
10/09/19 Piper Sandler
Catalyst should see limited impact from Ruzurgi launch, says Piper Jaffray
08/08/19 Cantor Fitzgerald
Catalyst price target raised to $12 from $10 at Cantor Fitzgerald
08/08/19 Truist
SunTrust says buy Catalyst on weakness, boosts price target to $11
CBMG Cellular Biomedicine
$17.46 /

-0.03 (-0.17%)

11/12/19 Baird
Cellular Biomedicine downgraded to Neutral at Baird
11/12/19 Baird
Cellular Biomedicine downgraded to Neutral from Outperform at Baird
09/17/19
Fly Intel: Top five analyst initiations
09/17/19 BTIG
Cellular Biomedicine initiated with a Buy at BTIG
ENZ Enzo Biochem
$2.58 /

+0.045 (+1.78%)

EPGNY Epigenomics
$0.00 /

+ (+0.00%)

EPIX Essa Pharma
$5.69 /

-0.06 (-1.04%)

10/25/19
Fly Intel: Top five analyst initiations
10/24/19 Oppenheimer
Oppenheimer starts Essa Pharma with Outperform rating, $8 price target
10/24/19 Oppenheimer
Essa Pharma initiated with an Outperform at Oppenheimer
EVFM Evofem
$6.11 /

+0.05 (+0.83%)

12/18/19 Roth Capital
Evofem's Amphora getting closer to FDA approval, says Roth Capital
12/11/19 H.C. Wainwright
Evofem price target raised to $11 from $9 at H.C. Wainwright
10/16/19 Cantor Fitzgerald
Evofem assumed with an Overweight at Cantor Fitzgerald
04/12/19 Cantor Fitzgerald
Evofem financing removes near-term capital concerns, says Cantor Fitzgerald
GNFTF Genfit
$0.00 /

+ (+0.00%)

04/15/19 Cantor Fitzgerald
Genfit data show CymaBay may be differentiated, says Cantor Fitzgerald
02/05/19 B. Riley FBR
Genfit initiated with a Buy at B. Riley FBR
GERN Geron
$1.49 /

+0.055 (+3.83%)

11/19/19 B. Riley FBR
B. Riley FBR resumes Geron with Buy rating, $4 price target
11/19/19 B. Riley FBR
Geron resumed with a Buy at B. Riley FBR
09/03/19 H.C. Wainwright
Geron initiated with a Buy at H.C. Wainwright
08/15/19 Cantor Fitzgerald
Geron initiated with an Overweight at Cantor Fitzgerald
HCM Hutchison China MediTech
$28.32 /

-0.01 (-0.04%)

11/19/19 CLSA
Hutchison China MediTech initiated with a Buy at CLSA
10/23/19 BofA
Hutchison China MediTech resumed with a Buy at BofA/Merrill
07/05/19 Macquarie
Hutchison China MediTech initiated with an Outperform at Macquarie
03/27/19 HSBC
Hutchison China MediTech initiated with a Buy at HSBC
LCTX Lineage Cell Therapeutics
$0.74 /

-0.0074 (-0.99%)

MRKR Marker Therapeutics
$3.06 /

-0.15 (-4.67%)

11/13/19 Piper Sandler
Marker Therapeutics price target lowered to $6 from $10 at Piper Jaffray
07/03/19
Oppenheimer bullish on Marker Therapeutics, initiates with an Outperform
07/03/19 Oppenheimer
Marker Therapeutics initiated with an Outperform at Oppenheimer
05/30/19 Roth Capital
Marker Therapeutics initiated with a Buy at Roth Capital
MEIP MEI Pharma
$2.36 /

+0.16 (+7.27%)

02/12/19 BTIG
MEI Pharma initiated with a Buy at BTIG
WVE Wave Life Sciences
$7.97 /

+0.11 (+1.40%)

01/02/20 H.C. Wainwright
H.C. Wainwright cuts Wave Life price target to $20, but 'not throwing in towel'
12/31/19
Fly Intel: Top five analyst actions
12/31/19 Guggenheim
Wave Huntington's data 'mediocre, but not a zero,' says Guggenheim
12/31/19 Truist
Wave Life Sciences price target lowered to $20 from $27 at SunTrust
VTVT vTv Therapeutics
$2.27 /

+0.24 (+11.82%)

05/30/19 H.C. Wainwright
vTv Therapeutics initiated with a Buy at H.C. Wainwright
05/06/19 Northland
vTv Therapeutics upgraded to Outperform from Market Perform at Northland
05/06/19 Northland
vTv Therapeutics upgraded to Outperform from Market Perform at Northland
STRO Sutro Biopharma
$11.83 /

+0.04 (+0.34%)

01/13/20 Truist
Sutro Biopharma initiated with a Buy at SunTrust
10/07/19
Fly Intel: Top five analyst initiations
10/07/19 BTIG
Sutro Biopharma initiated with a Buy at BTIG
09/05/19 JMP Securities
Sutro Biopharma resumed with an Outperform at JMP Securities
SBBP Strongbridge Biopharma
$2.30 /

+0.02 (+0.88%)

09/24/19 Evercore ISI
Strongbridge Biopharma initiated with an Outperform at Evercore ISI
09/24/19
Fly Intel: Top five analyst initiations
09/24/19 Jefferies
Strongbridge Biopharma initiated with a Buy at Jefferies
09/24/19 Jefferies
Strongbridge Biopharma initiated with a Buy at Jefferies
SELB Selecta Biosciences
$2.94 /

+ (+0.00%)

03/18/19 Canaccord
Selecta Biosciences price target cut to $13 from $25 at Canaccord
02/04/19 Mizuho
Selecta Biosciences price target lowered to $4 from $19 at Mizuho
01/28/19 Needham
Selecta Biosciences price target lowered to $12 from $28 at Needham
RIGL Rigel Pharmaceuticals
$2.73 /

+0.115 (+4.40%)

01/13/20 Piper Sandler
Rigel still one of the most under-appreciated stories in sector, says Piper
11/15/19
Fly Intel: Top five analyst initiations
11/15/19 Cantor Fitzgerald
Rigel Pharmaceuticals assumed with an Overweight at Cantor Fitzgerald
09/26/19
Fly Intel: Top five analyst initiations
PLSE Pulse Biosciences
$14.24 /

+0.2 (+1.42%)

02/25/19
Fly Intel: Top five analyst initiations
02/25/19 H.C. Wainwright
Pulse Biosciences initiated with a Buy at H.C. Wainwright
PTGX Protagonist Therapeutics
$7.16 /

+0.3 (+4.37%)

01/07/20 BTIG
Sarepta, Pacira, Protagonist named top 2020 Biotech picks at BTIG
12/04/19 Nomura Instinet
Nomura Instinet 'aggressive buyers' of Protagonist after yesterday's selloff
11/26/19 Nomura Instinet
La Jolla failure a positive for Protagonist Therapeutics, says Nomura Instinet
11/08/19 Nomura Instinet
Protagonist selloff yesterday a buying opportunity, says Nomura Instinet

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.